Oncology
Peloton Therapeutics Inc. is focused on clinical research in cancer, with activity centered on a kidney malignancy linked to inherited disease.
- Renal cell carcinoma
- Kidney cancer
The sponsor’s funded research reflects a targeted interest in malignancies arising in the renal setting.
Genetic and hereditary disease-associated cancer
Its clinical research landscape includes cancer associated with von Hippel-Lindau disease, highlighting interest in inherited conditions that predispose to tumor development.
- Von Hippel-Lindau disease
- Hereditary cancer
The sponsor is active in a disease area where genetic predisposition and tumor biology intersect.
Urologic oncology
Research activity is directed toward cancers of the urinary system, particularly tumors affecting the kidney.
- Urologic malignancy
- Renal tumor
This places the sponsor within a therapeutic domain concerned with solid tumors of the genitourinary tract.
Targeted therapy research
The funded clinical work is centered on PT2977 (belzutifan), indicating interest in mechanism-based treatment strategies for kidney cancer.
- Belzutifan
- PT2977
Its research focus includes therapies intended for VHL-related tumors and associated renal disease.
